Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2019, with a specific transaction date of July 24, 2019. The document serves as a transaction notification regarding share allocations for Non-Executive Directors under the company's share allocation arrangements for the service period of April 1, 2019, to June 30, 2019.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific equity transactions involving the following instruments and prices:
- Ordinary Shares (GBP): Priced at £16.54 per share.
- American Depositary Shares (ADSs) (USD): Priced at $41.14 per ADS.
Material Changes and Transaction Details
The filing reports the acquisition of notional shares by seven Non-Executive Directors. There are no material changes to the company's operations or financial position reported in this document. The specific transactions are as follows:
| Director Name | Position | Instrument | Volume Acquired | Price |
|---|---|---|---|---|
| Sir Philip Hampton | Non-Executive Chairman | Ordinary Shares | 2,645.103 | £16.54 |
| Mr Vindi Banga | Senior Independent Non-Executive Director | Ordinary Shares | 547.914 | £16.54 |
| Dr Vivienne Cox | Independent Non-Executive Director | Ordinary Shares | 434.553 | £16.54 |
| Ms Lynn Elsenhans | Independent Non-Executive Director | ADSs | 1,202.621 | $41.14 |
| Dr Laurie Glimcher | Independent Non-Executive Director | ADSs | 1,336.245 | $41.14 |
| Dr Jesse Goodman | Independent Non-Executive Director | ADSs | 403.177 | $41.14 |
| Ms Judy Lewent | Independent Non-Executive Director | ADSs | 449.255 | $41.14 |
| Mr Urs Rohner | Independent Non-Executive Director | Ordinary Shares | 547.914 | £16.54 |
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of director share transactions.
Investor Verification Checklist
- Verify the total number of shares allocated to Non-Executive Directors for the Q2 2019 period against the company's annual proxy statement or remuneration report.
- Confirm the exchange rate used to value the Ordinary Shares versus ADSs if comparing total compensation value across currencies.
- Check subsequent filings to ensure these notional acquisitions were settled or converted as per the company's share allocation policy.